Frank Muehlenbeck

Managing Director at EMBL Ventures GmbH

Frank Muehlenbeck

Frank Muehlenbeck

Managing Director at EMBL Ventures GmbH

Overview
RelSci Relationships

260

Number of Boards

13

Birthday

1971

Age

48

Contact Data
Trying to get in touch with Frank Muehlenbeck? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Frank Muehlenbeck likely has professional access to. A relationship does not necessarily indicate a personal connection.

Venture Partner at EMBL Ventures GmbH

Relationship likelihood: Strong

Chief Financial Officer at Affimed NV

Relationship likelihood: Strong

Chief Executive Officer at Affimed NV

Relationship likelihood: Strong

Chief Executive Officer at Sonetik AG

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Amphivena Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Operating Officer at Ion Torrent Systems, Inc.

Relationship likelihood: Strong

Professional at Biopharma Consulting Services LLC

Relationship likelihood: Strong

President & Director at Haemosan, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Pharvaris BV

Relationship likelihood: Strong

Professional at Affimed NV

Relationship likelihood: Strong

Paths to Frank Muehlenbeck
Potential Connections via
Relationship Science
You
Frank Muehlenbeck
Managing Director at EMBL Ventures GmbH
Education

The University of Stuttgart is especially known for its excellent reputation in the fields of advanced automotive engineering.

Career History
Managing Director
2015 - Current

EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties.The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position.EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept.

Partner
2008 - 2015

Aeris Capital is an active manager which invests in innovative small and medium-sizedcompanies in a range of sectors including biotechnology, communications, computer software, food, internet technology and medical.The firm typically participates in start-up, buy-out and expansion/development transactions, mainly in companies in the US, Austria, Germany and Switzerland.

Partner
2000 - 2008
Boards & Committees
Member-Supervisory Board
Prior - 2015

Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Member-Supervisory Board
2015 - Prior

Curetis NV engages in the manufacture, research and development, and commercialization of molecular microbiology solutions. It offers unyvero platform, which comprsises of the unyvero system with the A50 analyzer at its core, proprietary software, and single-use, application-specific cartridges. The company was founded by Johannes Bacher, Gerd Luedke and Andreas Boos in August 2007 and is headquartered in Holzgerlingen, Germany.

Member, Supervisory Board
2007 - Prior

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Frank Muehlenbeck. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Frank Muehlenbeck's profile does not indicate a business or promotional relationship of any kind between RelSci and Frank Muehlenbeck.